The Diagnosis of cancer can be overwhelming. At Cornell, we utilize a multidiciplinary team approach in the treatment of patients with lung and esophageal cancers. Our dedicated team is involved from the initial evaluation through the completion of a patient's post-operative course. This unparalleled attention to the patient helps to ease the burden of the diagnosis. For those of us involved in research as well as care, this is a very important time -- several novel treatment approaches recently have been developed here at Cornell, and we currently are showing promising results."For more information:
Minimal Access Surgery Center
Dr. Jeffrey Port is an Associate Professor of Cardiothoracic Surgery and an Attending Surgeon within the Division of Thoracic Surgery at New York Presbyterian-Weill Cornell Medical Center.
Dr. Port earned his medical school degree and also finished his general surgery residency at the New York University School of Medicine. He then completed his cardiothoracic surgical training at Weill Cornell Medical Center, where he developed an interest in thoracic oncology, specifically in lung and esophageal cancer.
As an attending thoracic surgeon at Weill Cornell Medical Center, Dr. Port specializes in lung and esophageal cancers, mediastinal tumors and Barrett's Esophagus. He also specializes in the area of minimally invasive thoracoscopic pulmonary surgery and the treatment of emphysema patients who require lung volume reduction.
Dr. Port has authored numerous journal articles and book chapters on immunotherapy for the treatment of lung and esophageal cancer, as well as the development of vaccines. He is currently researching COX-2 inhibitors and minimally invasive thoracoscopic surgery.
Dr. Port resides with his family here in Manhattan.
